Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study.
biomarker
circulating endothelial cells (CECs)
glioblastoma
perfusion MRI
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
08
02
2021
accepted:
23
03
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Glioblastoma (GB) is an aggressive tumor type and the detection of circulating endothelial cells (CECs) in peripheral blood has been related to angiogenesis. A prospective single-center pilot study of CEC detection at diagnosis in 22 patients with GB was performed, using the US FDA-approved CellSearch system. A CEC cutoff value was estimated using a receiver operating curve (ROC) and patients were classified into two groups: <40 CEC/4 ml and >40 CEC/4 ml blood. Median overall survival was 25.33 months for group 1 and 8.23 months for group 2 cases (p = 0.02). There was no correlation between CEC and PWI (perfusion-weighted imaging) RM. CEC detection has a prognostic value in GB cases at diagnosis.
Identifiants
pubmed: 35662744
doi: 10.2144/fsoa-2022-0008
pmc: PMC9136629
doi:
Types de publication
Journal Article
Langues
eng
Pagination
FSO796Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure The study was supported by Grupo Español de Investigación en Neurooncologia (GEINO). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Références
Ann Oncol. 2010 Sep;21(9):1765-1771
pubmed: 20233745
Neoplasia. 2006 Feb;8(2):79-88
pubmed: 16611400
J Clin Neurosci. 2015 Nov;22(11):1802-8
pubmed: 26308396
J Neurosurg. 2010 Jan;112(1):43-9
pubmed: 19522573
J Pharmacol Exp Ther. 2010 Dec;335(3):693-702
pubmed: 20826566
Nature. 2010 Dec 9;468(7325):824-8
pubmed: 21102434
Ann Oncol. 2004 Jan;15(1):139-45
pubmed: 14679134
Nat Med. 2004 Feb;10(2):145-7
pubmed: 14745444
J Thorac Oncol. 2009 Feb;4(2):208-13
pubmed: 19179898
PLoS One. 2013 Jul 29;8(7):e69034
pubmed: 23922679
Cancer. 1996 Jan 15;77(2):362-72
pubmed: 8625246
Neoplasia. 2009 Aug;11(8):771-9
pubmed: 19649207
Curr Stem Cell Res Ther. 2010 Dec;5(4):294-302
pubmed: 20528750
Acta Neurol Belg. 2013 Mar;113(1):7-11
pubmed: 22688590
J Thromb Haemost. 2020 Oct;18(10):2744-2750
pubmed: 32762140
Cor Vasa. 1992;34(4):359-64
pubmed: 1308729
Blood. 2006 Jul 15;108(2):452-9
pubmed: 16543470
Cancer Cell. 2007 Jan;11(1):83-95
pubmed: 17222792
Neurosurgery. 2009 May;64(5):819-26; discussion 826-7
pubmed: 19404145
Clin Cancer Res. 2009 Dec 15;15(24):7652-7657
pubmed: 19996223
Ann Oncol. 2010 Dec;21(12):2382-2389
pubmed: 20497963
Biomaterials. 2011 Jun;32(17):4140-50
pubmed: 21419482
NMR Biomed. 2006 Jun;19(4):463-75
pubmed: 16763973
Br J Cancer. 2015 Jul 14;113(2):226-31
pubmed: 26042933
Neuro Oncol. 2016 Jun;18(6):779-89
pubmed: 26527735
Epilepsy Curr. 2005 Mar-Apr;5(2):72-4
pubmed: 16059441
Int J Infect Dis. 2021 Jun;107:232-233
pubmed: 33965598
J Autoimmun. 2010 Mar;34(2):105-10
pubmed: 19656656
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Neurooncol. 2006 Jul;78(3):281-93
pubmed: 16554966